In vivo inhibition of tumor growth by cyclic adenosine 3',5'-monophosphate derivatives.
D000818:Animals; D001551:Benz(a)Anthracenes; D003994:Bucladesine / Q000627:therapeutic use; D002273:Carcinogens; D002279:Carcinoma 256, Walker / Q000188:drug therapy; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy; D000242:Cyclic AMP / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use*; D004273:DNA, Neoplasm / Q000096:biosynthesis; D004305:Dose-Response Relationship, Drug; D004967:Estrogens / Q000378:metabolism; D005260:Female; D005354:Fibrosarcoma / Q000188:drug therapy; D008113:Liver Neoplasms / Q000188:drug therapy; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000188:drug therapy; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000139:chemically induced / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism; D009607:Nitrosourea Compounds; D051381:Rats; D011919:Rats, Inbred Strains; D012260:Ribonucleases / Q000378:metabolism; D012513:Sarcoma, Experimental / Q000188:drug therapy; D014184:Transplantation, Homologous
D001551:Benz(a)Anthracenes; D002273:Carcinogens; D004273:DNA, Neoplasm; D004967:Estrogens; D009607:Nitrosourea Compounds; D003994:Bucladesine; D000242:Cyclic AMP; D012260:Ribonucleases